Ten63 Therapeutics
In silico drug design based on movement
* Data source: Crunchbase
- Founded
- 2018
- Employees*
- 2-10
- Funding to Date*
- undisclosed
- Website
- Ten63tx.com
Our software has made it possible — for the first time — to discover how a tumor will mutate, years before it actually happens in a patient. We can “discover” it while we are designing the drug itself in the computer. And so we can design drugs that work not just against the tumor before it mutates, but the drug will still work after it mutates. And not just one mutation — all likely mutations.
Currently only 2-4% of drug targets are both druggable and disease modifying
Ten63 Therapeutics improves human health by developing potent therapeutics against medically-validated, yet “undruggable” targets. We do this by combining low-residual, ML-based computational chemistry and mathematically-guaranteed, superlinear search algorithms to find optimized drug candidates when no one else can.